Pyrimidine antagonists, for example, 5-fluorouracil (5-FU), cytarabine (ara-C) and gemcitabine (dFdC), are widely used in chemotherapy regimes for colorectal, breast, head and neck, non-small-cell lung cancer, pancreatic cancer and leukaemias. Extensive metabolism is a prerequisite for conversion of these pyrimidine prodrugs into active compounds. Interindividual variation in the activity of metabolising enzymes can affect the extent of prodrug activation and, as a result, act on the efficacy of chemotherapy treatment. Genetic factors at least partly explain interindividual variation in antitumour efficacy and toxicity of pyrimidine antagonists. In this review, proteins relevant for the efficacy and toxicity of pyrimidine antagonists will be summarised. In addition, the role of germline polymorphisms, tumourspecific somatic mutations and protein expression levels in the metabolic pathways and clinical pharmacology of these drugs are described. Germline polymorphisms of uridine monophosphate kinase (UMPK), orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and methylene tetrahydrofolate reductase (MTHFR) and gene expression levels of OPRT, UMPK, TS, DPD, uridine phosphorylase, uridine kinase, thymidine phosphorylase, thymidine kinase, deoxyuridine triphosphate nucleotide hydrolase are discussed in relation to 5-FU efficacy. Cytidine deaminase (CDD) and 5 0 -nucleotidase (5NT) gene polymorphisms and CDD, 5NT, deoxycytidine kinase and MRP5 gene expression levels and their potential relation to dFdC and ara-C cytotoxicity are reviewed.
INTRODUCTION
Pyrimidine antagonists belong to the group of antimetabolite anticancer drugs and show structural resemblance with naturally occurring nucleotides (see Figure  1 ). Their action is accomplished through incorporation as false precursor in DNA or RNA or through inhibition of proteins involved in nucleotide metabolism. The most commonly used pyrimidine antagonists are 5-fluorouracil (5-FU), gemcitabine (dFdC) and cytarabine (ara-C). Newer oral variants of 5-FU are capecitabine and tegafur. 5-FU and its analogues are used, for example, in the treatment of colorectal, breast and head and neck cancer, [1] [2] [3] whereas dFdC is especially prescribed for non-small-cell lung cancer and pancreatic cancer. 4, 5 Ara-C is used in the treatment of leukaemia. 6 All pyrimidine antagonists are prodrugs and intracellular conversion into cytotoxic nucleosides and nucleotides is needed to produce cytotoxic metabolites. Proteins, involved in pyrimidine metabolism, handle these synthetic drugs, as if they were naturally occurring substrates. The extensive metabolism of pyrimidine antagonists implies that the intracellular concentrations of cytotoxic metabolites, thus indirectly the potential antitumour effects, largely depend on intracellular metabolic enzyme activity.
The aim of this review is to summarise pharmacogenomic data regarding proteins related to the efficacy and toxicity of pyrimidine antagonists and to identify potential predictive and/or prognostic genetic factors for toxicity and treatment outcome. The impact of germline polymorphisms as well as tumour-specific somatic mutations and protein expression levels on the clinical pharmacology and metabolic pathways of these drugs will be discussed.
Metabolic Pathways of Pyrimidine Antagonists

5-Fluorouracil
The anabolic conversion of 5-FU into nucleotides is essential for its action. Several enzymes of the pyrimidine metabolic pathway are required for the conversion of 5-FU to nucleotides. 7 Cytotoxic nucleotides can be formed by three routes, as illustrated in Figure 2: (1) conversion of 5-FU to 5-fluoro-uridine-monophosphate (FUMP) by orotate phosphoribosyl transferase (OPRT); (2) sequential conversion of 5-FU to FUMP by uridine phosphorylase (UP) and uridine kinase; (3) sequential conversion of 5-FU to 5-fluoro-deoxyuridine-monophosphate (FdUMP) by thymidine phosphorylase (TP) and thymidine kinase (TK). 8 The antitumour activity results from inhibition of thymidylate synthase (TS) by FdUMP, as well as from incorporation of 5-FU metabolites into RNA and DNA. Only a small part of the 5-FU dose is activated via these routes, as in humans 80-90% of the administered dose is degraded to 5,6 dihydrofluorouracil (DHFU) by dihydropyrimidine dehydrogenase (DPD). DHFU can be further degraded to fluoro-b-ureidopropionate (FUPA) by dihydropyrimidinase (DPYS) and subsequently to fluoro-b-alanine (FBAL) by b-ureidopropionase (BUP1). 5-FU degradation occurs in all tissues, including tumour tissue, but is highest in the liver. 9 
Capecitabine and tegafur
Capecitabine is an oral prodrug of 5-FU. After absorption from the gut, capecitabine is converted into 5 0 -deoxy-5-fluorocytidine (5 0 -dFCR) by carboxyl-esterase in the liver, and subsequently further converted into 5 0 -deoxy-5-fluorouridine (5 0 -dFUR) by cytidine deaminase (CDD). Finally, 5-FU results from bioconversion of 5 0 -dFUR by TP 10 (see Figure  2 ). Tegafur is another oral 5-FU prodrug, that is converted into 5-FU by cytochrome P450 (CYP450) enzymes in the liver. CYP2A6 is the main CYP450 enzyme involved in tegafur activation, but CYP1A2 and CYP2C8 also play a role (see Figure 2) . Tegafur is combined with uracil in a molar proportion of 1 : 4 available in the commercial preparation UFT s . Uracil is a competitive substrate for DPD and its role in UFT s is to diminish 5-FU catabolism by DPD. dFdC and ara-C
The metabolic pathways of dFdC and ara-C are almost alike 11, 12 (see Figure 3 ). Membrane transport of both dFdC and ara-C is mediated by equilibrative nucleoside transporters. Subsequently, dFdC is phosphorylated into dFdC monophosphate (dFdCMP) by deoxycytidine kinase (dCK). The same enzyme is responsible for the intracellular phosphorylation of ara-C into cytarabine monophosphate (ara-CMP). dCK is the rate-limiting enzyme in the biotransformation of both dFdC and ara-C. Inactivation of dFdCMP and ara-CMP can occur through dephosphorylation by 5 0 -nucleotidase (5NT). Monophosphates, escaping from dephosphorylation are available for further phosphorylation into di-and triphospates by dCMP kinase and nucleoside diphosphate kinase, respectively. dFdC diphosphate (dFdCDP) is a potent inhibitor of the enzyme ribonucleotide reductase (RNR), which will lead to depletion of deoxycytidine diphosphate (dCDP) and deoxycytidine triphosphate (dCTP) in the cell. This may favour the incorporation of dFdCTP into DNA. Moreover, dFdC has the unique property that, after incorporation of dFdC monophosphate in DNA, one more deoxynucleotide molecule can be inserted. This stops DNA polymerase. 13 This pattern is distinct from that of ara-C, which halts polymerase progression at the analogue insertion site. The masked termination of dFdC makes the inserted analogue more resistant to removal from DNA.
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Other differences with ara-C are the faster membrane transport velocity of dFdC, the greater effectiveness of dFdC phosphorylation by dCK and the longer intracellular retention of dFdCTP. These factors may, at least in part, explain the different spectra of antitumour activity of both drugs. Only a small part of the dFdC and ara-C dose is responsible for the cytotoxic effects, since more than 90% of the dose is inactivated by the enzyme CDD into dFdU and uracil-arabinoside (ara-U), respectively.
Germline Polymorphisms and Fluoropyrimidine Efficacy
5-Fluorouracil
Genetic polymorphisms of enzymes involved in the metabolic activation pathway of 5-FU have been described for the enzymes uridine monophosphate kinase (UMPK) and orotate phosphorylase transferase (OPRT). Three allelic variants of UMPK have been recognised in the human population: UMPK1, UMPK2 and UMPK3. 14 The UMPK1 allele is associated with about three times the catalytic activity of the UMPK2 allele. Therefore, UMPK2 homo- zygotes are relatively deficient of total UMPK enzyme. The allele frequency of UMPK1 is about 95-97% and that of UMPK2 3-5%, in both Caucasians and Asians. [15] [16] [17] UMPK3 is rarely seen. The consequences of this polymorphism for 5-FU chemotherapy have not yet been studied.
In the OPRT gene, a G213A mutation in exon 3 and a 440G mutation in exon 6 have been observed, with allele frequencies of 26 and 27%, respectively. 18 Both mutations do not significantly compromise in vitro OPRT activity, and therefore it seems unlikely that they affect 5-FU-antitumour efficacy.
Additionally to the 5-FU-activating enzymes, far more information is available regarding polymorphisms of target enzyme TS. For TS, at least five genotypes have been identified, characterised by variable numbers of a 28-bp tandem repeat sequence in the DNA promoter enhancer region (TSER). So far, alleles containing 2 (TSER*2), 3 (TSER*3), 4 (TSER*4), 5 (TSER*5) and 9 (TSER*9) copies of the tandem repeat have been identified. 19 The double and triple repeats are the predominant alleles. The triple tandem genotype is associated with higher TS mRNA and TS protein levels compared to the double tandem genotype. [20] [21] [22] [23] The effect of higher numbers of repeats is not yet clear. The allele frequency of TSER*3 appears almost similar in Asians, Africans and Caucasians (about 50%), but the frequency of homozygous TSER*3 was reported to be significantly higher in Asians (67%) compared to Caucasians (38%). 24 The TSER*4 and TSER*9 alleles are found in higher frequencies in African populations (2-7%) compared to Caucasians (0-1%). 25 The consequences of the TSER genotype for fluoropyrimidine chemosensitivity have been studied in both tumour cell lines and clinical trials. In two studies with tumour cell lines, the TSER polymorphism had no effect on 5-FU chemosensitivity. 26, 27 Contrary to in vitro data, in 65 patients with rectal cancer, tumour downstaging after preoperative 5-FU-based chemoradiation was observed in only 22% of homozygotes for triple tandem repeat sequences compared to 60% of patients who were heterozygous or homozygous for double tandem repeats. 28 In another small retrospective study of 24 patients with metastatic colorectal cancer, three out of four homozygous TSER*2 patients responded on capecitabine, whereas only one out of 12 of heterozygotes and two out of eight homozygous TSER*3 patients responded. 29 Furthermore, in a study of 221 patients with Dukes C colorectal cancer, patients homozygous for TSER*3 gained no survival benefit from 5-FU treatment, whereas survival was increased in heterozygotes and patients homozygous for TSER*2. 30 However, the TSER genotype did not seem to be an efficacious marker for tumour sensitivity to 5-FU-based oral adjuvant chemotherapy in 135 Japanese colorectal patients. 31 Surprisingly, in a small study of 54 colorectal cancer patients, not the TSER*2 but the TSER*3 genotype correlated with an increased disease-free survival after adjuvant 5-FU chemotherapy. 32 Several factors can possibly explain these inconclusive data. Firstly, within the second 28 bp tandem repeat sequence, a G/C polymorphism was recently discovered. Functional analysis revealed that the TSER*3/G genotype has three to four times greater efficiency of translation than other polymorphic sequences. 33, 34 In a study of the G/C polymorphism in 258 primary colorectal tumours, it was found that all low-expression genotypes were associated with longer survival after adjuvant fluoropyrimidine chemotherapy, whereas no benefit was seen for high-expression genotypes. 33 Secondly, a 6 bp deletion genotype (TS1494del6) in the 3 0 untranslated region of the TS gene has been associated with reduced TS mRNA stability. 35, 36 The frequency of this genotype was found to be 41% in non-Hispanic whites, 26% in Hispanic whites, 52% in African-Americans and 76% in Singapore Chinese. The relative instability of TSmRNA may have its effect on TS protein activity and thus indirectly on fluoropyrimidine chemosensitivity. However, this polymorphism was not directly related to in vitro chemosensitivity in tumour cell lines 27 or disease-free survival after adjuvant 5-FU chemotherapy in a small study of 54 colorectal cancer patients. 32 Another cause of conflicting data is the loss of heterozygosity (LOH), that is frequently observed for TS. 37 The TS gene is located on chromosome 18p11.32, a region most frequently lost in colorectal cancer. In a small study of 30 stage IV colorectal cancer patients, LOH was observed in 17 out of 22 heterozygotes. 38 The presence of a TSER*3 allele (homozygous TSER*3, heterozygous and TSER*3/loss) was associated with lower survival on fluoropyrimidine chemotherapy. LOH in tumour tissue is a significant factor, to be taken into account when TS genotypes are to be considered for outcome prediction. It is important to bear in mind that LOH limits the use of germline DNA from for example, blood for predictive genotyping.
Finally, it must be stressed that many studies of the TS polymorphism were underpowered to detect relations of the different genotypes with clinical outcome. Hence, the exact consequences of the triple tandem repeat genotypes for 5-FU chemosensitivity are not yet clear. Sufficiently powered clinical trials and additional mechanistic studies may be needed to elucidate the cause of so far unexpected outcomes.
Directly linked to the 5-FU-mediated inhibition of TS is the presence of intracellular folate. A polymorphism that may influence the efficacy of 5-FU and its analogues by influencing folate pools is that of the methylene tetrahydrofolate reductase (MTHFR) gene. MTHFR catalyses the conversion of 5,10-methyltetrahydrofolate to 5-methyltetrahydrofolate. 5,10-Methyltetrahydrofolate is an essential cofactor in the biosynthesis of dTMP (see Figure 2) . The dissociation of FdUMP from the ternary complex with TS and 5,10-methyltetrahydrofolate is suppressed when levels of 5,10-methyltetrahydrofolate are increased. 39 So far, two MTHFR polymorphisms have been recognised. A common C677T transition in exon 4 of the MTHFR gene results in a thermolabile enzyme variant with lower specific activity. 40 The second polymorphism concerns a codon 1298 A to C transition in exon 7, which is also associated with decreased enzymatic activity. 41 In vitro transfection of mutant 677T MTHFR cDNA in colon and breast cancer cells increased the chemosensitivity of these cells to 5-FU, suggesting at least a modulating role of this genotype on cellular fluoropyrimidine sensitivity. 42 The geographic and ethnic distribution of the 677T genotype was studied by Wilcken et al. 43 The homozygote T genotype was found to be particularly common in northern China (20%), southern Italy (26%) and Mexico (32%). In two studies with, respectively, 45 and 51 colorectal cancer patients, the 677T genotype appeared to affect the folate pool. 44, 45 In the latter study, no effect was seen of the 677T genotype on overall survival after oral 5-FU-based chemotherapy. 45 Contrary to this, in a study of 43 metastatic colorectal cancer patients receiving fluoropyrimidine-based chemotherapy, the presence of one or two mutant alleles was associated with increased tumour response. 46 In a recent study of 98 dissiminated colorectal cancer patients, the C677T mutation was also associated with higher response rates on 5-FU/folinic acid chemotherapy. 47 In the same study, the A1298C polymorphism was studied, but this was not related to the response rate. The exact roles of the MTHFR polymorphisms have to be elucidated in larger prospective clinical trials.
Besides the above-mentioned polymorphisms in the 5-FU anabolic route, genetic variations in 5-FU catabolic enzymes can also have a profound effect on 5-FU toxicity. At least the phenomenon of inherited DPD deficiency is an important issue. DPD deficiency is caused by molecular defects in the DPD gene that result in complete or partial loss of DPD activity. 48 This can cause extreme 5-FU toxicity. So far, 33 different mutations have been identified in the dihydropyrimidine dehydrogenase (DPYD) gene. At least 11 of these 33 mutations, including one polymorphism, were detected in patients suffering from severe 5-FU-associated toxicity. [48] [49] [50] In patients who are deficient for DPD, 5-FU clearance is dramatically reduced and standard doses of 5-FU cause excessive toxicity in these patients. 48, 51, 52 The frequency of DPD deficiency has been estimated to be as high as 2-3% in Caucasians based on measurements of DPD activity in peripheral mononuclear cells in patients and healthy volunteers 53, 54 This percentage is probably high enough to justify screening on DPD deficiency prior to 5-FU-based chemotherapy. Instead of screening for specific mutations in the DPYD gene, Mattison et al 55 developed a simple uracil breath test for DPD phenotyping, based on the release of 13 CO 2 from 2-13 C uracil in the presence of intact DPD. Expired air was collected 5-180 min after oral ingestion of 6 mg/kg 2-13 C uracil. Partially deficient DPD breath profiles Apart from DPD, it was recently discovered that deficiency in dihydropyrimidinase (DHP), the second enzyme in 5-FU catabolism, can also result in severe 5-FU toxicity. 57 At least six mutations have been identified in the the DHP encoding gene. Missense mutation G883A in exon 5 has been associated with severe 5-FU toxicity. 58 This mutation has been shown to result in mutant DHP enzyme without residual activity.
Capecitabine and tegafur
Polymorphisms in capacitabine-metabolising enzymes have only been reported for CDD. Since this polymorphism may also be relevant for dFdC and ara-C metabolism, it will be discussed in the next paragraph. Furthermore, mutations in CYP2A6 have recently been identified to affect tegafur metabolism. 59 Two mutant alleles, CYP2A6*4C and CYP2A6*11, were detected in a patient with largely reduced tegafur clearance. The prevalence of these mutations and its impact on clinical outcome are not yet clear.
Gemcitabine and ara-C
There are at least two polymorphisms in the metabolising pathway, that might be relevant for dFdC and ara-C toxicity and efficacy. Firstly, cloning of human CDD revealed two protein variants (CDD1 and CDD2) with different in vitro deamination rates of ara-C. 60 Theoretically, patients who deaminate dFdC or ara-C more efficiently are shorter exposed to the parent drugs, while faster metabolism of capecitabine results in increased 5-FU levels. In vitro transfection of human bladder cancer cells with CDD2 cDNA did increase CDD activity, and indeed made the cells more sensitive to 5 0 dFUR and capecitabine, but resistant to dFdC. 61 This warrants further investigation of the possible role of the CDD genotype in fluoropyrimidine chemosensitivity.
Secondly, 5 0 -NT deficiency is an autosomal recessive condition, known to cause haemolytic anaemia. Several mutations causing 5 0 -NT deficiency have been identified. 62 On theoretical grounds, in patients with 5 0 -NT deficiency, treatment with dFdC or ara-C may result in increased toxicity although this has not yet been published. An overview of polymorphic genes and related enzymes with possible relevance for fluoropyrimidine chemotherapy is presented in Table 1 .
Impact of Somatic Mutations And Gene Expression Levels: 5-FU and its Metabolic Enzymes
5-Fluorouracil
Data on expression levels of enzymes involved in the metabolic activation of 5-FU in relation to chemosensitivity are sparse. Low UMPK levels were observed in 29 colorectal tumour samples of patients with acquired 5-FU resistance. 63 Low OPRT as well as UP and UK activity has been associated with 5-FU resistance in tumour cell lines. [64] [65] [66] [67] The role of OPRT has also been investigated in a few clinical studies. High OPRT activity was associated with good in vitro sensitivity to 5-FU, measured by Collagen Gel Droplet Embedded Culture Drug Sensitivity test, Fluoresceine Diacetate Assay or Histoculture Drug Response Assay, in human colorectal cancer tissues. 68, 69 Furthermore, in 37 patients treated with oral tegafur-uracil for disseminated colorectal cancer, responding tumours had higher expressions of OPRT than nonresponding tumours. 70 In the same study, there was no difference in UP mRNA between responding and nonresponding tumours. The role of UP in 5-FU sensitivity is probably marginal, since transfection of tumour cells with UP cDNA did not affect fluoropyrimidine sensitivity. 71 More research is needed to establish the exact role of OPRT in 5-FU sensitivity.
Most research of fluoropyrimidine activation pathways has been focused on the role of TP. Results regarding the role of tumoral TP expression appear to be contradictory. In patients, high as well as low TP mRNA expression levels have been correlated with response to 5-FU therapy. An increase in both relapse-free survival and overall survival was suggested in TP-positive compared to TP-negative breast tumours in a small study of 109 patients treated with adjuvant cyclophosphamide, methotrexate and 5-FU (CMF). 72 Furthermore, in 38 metastatic colorectal cancer patients treated with 5-FU and leucovorin (LV), TP mRNA levels in nonresponding tumours were higher than in responding patients. 73 In 28 patients treated for advanced gastric cancer with 5-FU plus pirarubicin and cisplatin, high tumour tissue TP expression was associated with response on chemotherapy. 74 In another 126 advanced gastric cancer patients, TP overexpression was associated with increased patient survival after fluoropyrimidine chemotherapy, but correlated with unfavourable prognosis in patients not treated with fluoropyrimidines. 75 Consequently, it is hard to draw conclusions from current, in general small trials.
Taking a close look at 5-FU metabolism, one might expect that cells with higher TP levels would be more sensitive to 5-FU, due to higher FdUMP levels resulting from increased 5-FU activation (see Figure 2) . However, TP also functions as an angiogenesis factor since TP-and platelet-derived endothelial cell growth factor (ECGF1) have been recognised as the same protein. High TP gene expression might therefore be associated with a more aggressive and malignant tumour phenotype. 73 Transfection of cancer cells with TP cDNA has been performed in several in vitro studies to investigate the effect of TP overexpression on chemosensitivity. A clear correlation was found between TP activity and in vitro sensitivity to the 5-FU analogue 5 0 -dFUR, and to a lesser extent to 5-FU itself. [76] [77] [78] [79] [80] [81] Marchetti et al 76 also studied the effect of TP overexpression on in vivo tumour growth in a rat model. The impact on tumour growth turned out to be relatively modest and only involved the initial stages of tumour growth. These results suggest that tumour growth and chemosensitivity are independently related to TP 82 This may largely trouble the interpretation of data of in vivo PCR as well as immunohistochemistry (IHC) studies. Consequently, this aspect particularly has to be taken into account in study designs to validate TP as a predictive marker.
Data on the role of TK in 5-FU chemosensitivity are also contradictory. Chemosensitivity was unchanged in TKdeficient colon cancer cells compared to parent cells, suggesting only a marginal role of TK in 5-FU sensitivity. 83 In another study, TK overexpression has been associated with 5-FU resistance in gastric tumour cell lines, 66 but other groups found a reduction of TK activity in chemoresistant colon cancer cell lines. 65, 67 Intracellular availability of deoxyribose-1-phosphate might account for these differences, since the activation of 5-FU by TP and TK is fully dependent on the availability of this co-substrate. If cellular levels of this co-substrate are too low, hardly any 5-FU can be metabolised via this route. Only one patient study is available regarding tumour TK activity in relation to treatment efficacy. In this study, tumour TK activity could not be related to the efficacy of second-line 5-FU (poly)-chemotherapy in 121 advanced breast cancer patients who failed on first-line tamoxifen treatment. 84 Thus, TK is probably not a strong factor related to 5-FU sensitivity.
A route that has been extensively evaluated in relation to 5-FU chemoresistance is the intracellular biodegradation of 5-FU by DPD. In vitro experiments in human tumour cell lines demonstrated an inverse correlation between both DPD mRNA expression and activity with 5-FU response. 85 DPD mRNA levels were also related to primary 5-FU resistance in seven human gastrointestinal cell lines. 86 Furthermore, high DPD activity and DPD mRNA levels were correlated with low sensitivity to 5-FU in three human gastric, two colon, one breast and one pancreatic carcinoma xenografts in the nude mice model. 87 However, data of presently available clinical studies are less unequivocal. An overview of clinical relevant studies is presented in Table 2 . Most studies have been performed in colorectal cancer, 68, [88] [89] [90] [91] some in gastric, [92] [93] [94] head and neck, [95] [96] [97] and non-small-cell lung cancer, [98] [99] [100] and few in breast and bladder cancer. 101, 102 A number of studies have indicated that there is no strong link between DPD mRNA levels and DPD protein activity levels. It has been reported that DPD mRNA, but not DPD activity, is reduced in colorectal tumours compared with normal mucosa, although considerable overlap exists in measured mRNA levels. [103] [104] [105] [106] [107] [108] [109] [110] Reduced mRNA levels have also been reported in ovarian cancer. 111 DPD activity appears to be increased in breast cancer (see Table 3 ). 101, 112 This suggests that DPD is not only regulated at transcriptional and translational, but also at the posttranscriptional, level. This hampers the use of DPD mRNA as predictive marker for 5-FU efficacy. Inhomogeneity of tumour tissue samples may, in part, also account for conflicting results.
Summarising, it can be concluded that data on tumour expression levels of 5-FU metabolising enzymes in relation to chemosensitivity are sparse and that studies show conflicting results. This may at least partly be due to 
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small numbers and therefore lack of statistical power in the studies.
Capecitabine/tegafur
In the animal model, high TP/DPD ratios have been associated with antitumour efficacy of capecitabine and its metabolite 5 0 dFUR in human tumour xenografts. 113 In vivo, high TP/DPD ratios suggested a better clinical outcome after adjuvant treatment with 5 0 dFUR in a study of 88 colorectal cancer patients, and in 17 metastatic gastric cancer patients. 114, 115 TP expression was examined by IHC in 650 breast tumours of patients with early breast cancer receiving adjuvant 5 0 dFUR. 116 Eight-year follow-up data showed that high TP expression in the tumour was a favourable prognostic indicator. Thus, TP expression seems to be a predictive factor for 5 0 dFUR efficacy. Since the activation of tegafur depends on several CYP450 enzymes, interindividual variations in enzyme expression may affect the rate of tegafur metabolism. Indeed, the relative contribution of each enzyme is known to differ among patients, but the clinical consequences of this phenomenon are unclear. 117 
Impact of Somatic Mutations and Gene Expression Levels: 5-FU and its Target Enzymes
Contrary to enzymes related to the 5-FU metabolic activation pathway, the target enzyme TS has been extensively studied in relation to 5-FU efficacy. A large amount of preclinical in vitro data suggest a correlation between TS activity and sensitivity to 5-FU. In a panel of 19 nonselected breast, digestive tract and head and neck cancer cell lines, as well as in a panel of 13 nonselected human colon cancer cell lines, the TS activity was inversely correlated with 5-FU sensitivity. 85, 118 Several in vitro studies in tumour cell lines also suggest TS overexpression as a mechanism of resistance after repeated exposure to 5-FU. 86, 119, 120 Chemosensitivity to 5-FU was also increased after transfection of human colon cancer cells with antisense TS cDNA. 121 However, conflicting data have been observed in clinical studies evaluating the prognostic role of mRNA, protein and activity levels of TS in relation to tumour response and clinical outcome to 5-FU-based chemotherapy. An overview of relevant clinical studies is presented in Table 4 . Most studies regarding TS expression in relation to chemosensitivity have been performed in patients with disseminated colorectal cancer, 68, 91, [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] some in gastric cancer 94, [135] [136] [137] [138] and few studies in head and neck cancer, 95, 96, 139 non-small-cell lung cancer 99,100 pancreatic and breast cancer. 84, 140, 141 Several factors may account for the difficult interpretation of combined clinical data. Firstly, it has been reported that TS protein can downregulate its own translation, whereas its transcription is regulated by E2F, a cell cycle checkpoint regulator. Together, this results in low TS levels in stationary phase cells. Although cells with a low TS might theoretically Finally, the assay type may have influenced the outcome of some studies, since IHC as well as rt-PCR were used to measure TS expression. IHC has been performed using different types of antibodies, including monoclonal TS106 as well as polyclonal antibodies. Differences in binding specificity and selectivity may have had a decisive impact on study outcome. Furthermore, the issue of infiltrating cells disturbing tumour tissue homogeneity and thus troubling PCR data, as mentioned earlier when interpreting TP data, may also hold for TS.
Acknowledging the importance of TS expression in colorectal cancer, another determinant for 5-FU cytotoxicity may be the enzyme deoxyuridine triphosphate (dUTP) nucleotidohydrolase (dUTPase), which is the key regulator of dUTP pools. There are at least two isoforms of dUTPase, a nuclear and a mitochondrial form, encoded by the same gene. In tumour cell lines, increased dUTPase levels accounted for resistance to the 5-FU metabolite 5 0 dFUR. 144, 145 In a small retrospective study in tumours of 20 metastatic colorectal cancer patients, high nuclear dUTPase protein expression was associated with poor tumour response on 5-FU therapy. 146 However, larger studies are needed to establish the role of dUTPase in 5-FU chemoresistance.
Impact of Somatic Mutations and Gene Expression Levels: dFdC and ara-C Resistance to nucleoside analogues can be due to a number of factors, affecting drug metabolism, including increased deamination, loss of expression of activating kinases and increased activity of nucleotidases. In vitro, gene transfer of Pyrimidine antagonist pharmacogenetics
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CDD cDNA into murine fibroblast cells was shown to induce cellular resistance to ara-C through increased deamination. 147 In patients with acute myeloid leukaemia (AML), pretreatment CDD activity did correlate with response on ara-C induction treatment in two studies, both involving 36 patients. 148, 149 Ara-C resistance has also been associated with low dCK activity both in vitro 150, 151 and in 21 AML patients. 152 In turn, increased dCK activity was associated with increased activation of both compounds to cytotoxic nucleoside triphosphate derivates. However, mutational inactivation of dCK is not thought to confer resistance to ara-C in AML patients because mutations in the dCK gene are rarely found in refractory or relapsed AML patients. 153, 154 Alternatively, inactivation of dCK by the formation of alternatively spliced dCK transcripts has been demonstrated in seven out of 12 patients with resistant AML compared to one out of 10 patients with sensitive AML. 155 This mechanism is probably a cause of therapy failure in patients with resistant AML. 156 Finally, high 5NT expression in blast cells was shown to be an independent prognostic factor for poor outcome in 108 AML patients after ara-Ccontaining regimens. 157 The balance between dCK and 5NT might predict drug toxicity, since strongly increased 5NT activity combined with reduced dCK activity was observed in a human leukaemic cell line, resistant to ara-C and dFdC. 158 Apart from resistance to nucleoside analogues caused by aberrant drug metabolism, altered drug transport may cause decreased chemosensitivity. Recently, overexpression of the human multidrug resistance protein 5 (MRP5), an ABC transporter known to transport nucleotide monophosphates, has been associated with resistance to dFdC in vitro.
159 MRP5-mediated efflux of dFdC metabolites may lower the accumulation of dFdC in cells. So far, other chemoresistance-related transport mechanisms have not been identified for pyrimidine antagonists.
Other Proteins Related to Pyrimidine Antagonist Chemosensitivity As mentioned in the previous sections, expression levels of specific proteins, directly involved in drug metabolism of pyrimidine antagonists, may affect treatment efficacy. However, expression of genes related to cell growth and the apoptotic pathway may also affect chemosensitivity. This interaction of apoptosis regulator proteins with chemosensitivity is an intriguing issue, but an extensive analysis of current literature on this subject falls outside the scope of this review. The most extensively studied genes with regard to pyrimidine antagonist chemotherapy are bcl-2, bax, c-myc and p53. [160] [161] [162] [163] [164] [165] [166] [167] [168] Here, we will only briefly report on the putative role of p53 with respect to 5-FU efficacy, as this relationship has been most extensively studied. Mutations in the p53 gene and p53 overexpression have been associated with 5-FU chemoresistance both in vitro [169] [170] [171] and in vivo in colorectal, 124, [172] [173] [174] [175] head and neck, 176, 177 and breast cancer. 178 However, results in some other studies are less unequivocal. 179, 180 Recently, it has been suggested that only patients whose primary colorectal tumour contain amplified c-myc and wild-type p53 might benefit from 5-FU-based chemotherapy. 181 Interestingly, there is an increasing evidence of interactions between TS and p53. P53 gene mutation and protein overexpression are associated with increased TS mRNA levels and TS cytoplasmatic protein in colorectal tumours, 124, 128, 182 It has been demonstrated that wild-type p53 is able to bind TS mRNA, which results in a feedback regulation of TS protein synthesis. 183 In cells with mutated p53, this feedback mechanism fails and, as previously mentioned, overexpression of TS is associated with poor clinical outcome.
Impact of Current data on Clinical Practice
Summarising, we conclude that, in tumour material, none of the enzymes discussed above can currently function as predictive marker by itself. So far, only small studies have been performed and drawing conclusions from combined data of these often statistically underpowered studies is fairly impossible due to differences in applied techniques or patient groups. Clinical practice affecting studies are not available yet. Good predictive genetic markers or marker sets are lacking. The specificity of a predictive marker needs to be high, as it will be used to discriminate between treatment options. Probably, panels of genes will be needed to obtain an adequate specificity. To find such gene panels, far more studies are needed. Looking at current data, a combination of the expression of DPD, TS, TP and OPRT, all four crucial enzymes in the metabolism of 5-FU, at least appears to be a promising approach in colorectal cancer [68] [69] [70] [184] [185] [186] (Table 5 ).
Future Perspectives: The Polygenetic Approach Despite the here summarised potential genes and proteins interfering with pyrimidine antagonist metabolism, only few factors indeed have been proven to affect chemotherapy efficacy and/or toxicity. Most consistent data are available regarding the role of TS, DPD and p53 in 5-FU chemotherapy, and that of TP in capecitabine chemotherapy (see Tables 1 and 5 ). The impact of germline DPD deficiency on 5-FU pharmacokinetics and the development of severe lifethreatening toxicity is obvious. Whether or not to screen patients on DPD deficiency before starting chemotherapy is, however, an issue of debate. [187] [188] [189] Since genetic abberations in the DPYD gene explain less than half of all cases of extreme 5-FU-related toxicity, costly screening will only be partially preventive. Therefore, a solid cost-benefit analysis, preferentially embedded in a large prospective clinical trial, will be needed to establish the added value of DPYD genotyping. Screening (genotypically or phenotypically) might become standard clinical practice as soon as a rapid, sensitive and cheap test becomes available.
Regarding 5-FU efficacy, some attempts have been made recently to identify putative markers of response in tumour material for use in patient treatment guidance. 96, 138, 183, 190 However, despite some promising studies, the overall data are difficult to interpret and not always in line with previous results in larger patient groups. This might, at least in part, be due to the complexity in transcription and translation of Pyrimidine antagonist pharmacogenetics JG Maring et al some of the genes discussed above (eg TS). Additional mechanistic studies are needed to explore this issue more in detail. Furthermore, as mentioned before, many available studies are insufficiently powered to reach statistical significance. Therefore, incorporation of pharmacogenomic issues in future phase II and III clinical trials should be encouraged.
Another cause for inconsistency in current data may be found in the applied scientific methodology. A crucial factor in the search for predictive markers is the availability of a standardised, accurate, precise and robust test. Method validation, such as performed for the TS106 antibody for TS IHC, is a prerequisite for standardised testing. 191 Subsequently, these quality-controlled diagnostics should be tested not only retrospectively, but also in prospective multi-centre (and multi-laboratory) clinical trials. Unfortunately, such tests are not available yet.
Also causing inconsistency in the outcome of monogenetic studies may be the fact that the impact of other genes related to response and survival is ignored in the final calculations. Since cancer is a genetically heterogeneous disease, the monogenetic approach is likely too simple. This implies that far more research is needed to gain more insight into the exact role of genetic polymorphisms, and gene expression levels on pyrimidine antagonist chemotherapy. The interaction between TS and p53, combined with the impact of several TS polymorphisms, illustrates the complexity of pharmacogenomic research.
The two most important approaches in current and near future research to find predictive marker sets will be the candidate gene and the microarray strategies. A broad range of candidate genes to focus on in future research has been summarised in this review. On the other hand, further developments in microarray techniques and proteomics may eventually lead to the identification of a subset of relevant genes for a certain drug in a certain tumour type.
Few studies in cancer cell lines and cancer xenografts have already shown the possibilities of using cDNA microarray profiling for identification of novel genes involved in response or resistance to chemotherapy. [192] [193] [194] [195] Microarray analysis of 2400 genes revealed five novel 5-FU-inducible transcriptional target MCF-7 breast cancer cells (SSAT, annexin II, MAT-8, thymosin b-10 and chaperonin-10). 193 In another study, analysis of 9216 genes in a panel of 30 colon carcinoma cell lines revealed 420 genes that were correlated with 5-FU response. 194 Genes involved in DNA replication and repair (including MLH1, PCNA, replication factor C, nucleosome assemby protein 1, origin recognition complexes and topoisomerase II) and protein processing and targeting (including several chaperones, lectin mannose binding 1, heat shock 70 kDa protein 8, nucleophosmin and hypoxia upregulated 1) were significantly enriched for expression on the 430 gene list. Recently, Wang et al analysed gene expression in five pairs of 5-FU-resistant and parental cancer cell lines with a cDNA microarray approach. 195 They identified nuclear factor kappa B (NFKappaB) p65 as one of the genes related to 5-FU resistance and demonstrated that transfection of NFKappaB in MCF-7 cells induced 5-FU resistance.
These studies show the potential power of these techniques for identifying predictive markers for drug sensitivity, as well as novel targets to overcome drug resistance. In the near future, identification of relevant germline polymorphisms, combined with relevant mRNA expression levels in tumour tissue, might permit more effective, individualised cancer chemotherapy. Ideally, a process of 'chemotyping', that is, choosing the right chemotherapy regimen in the right dose, based on selected genotypical and phenotypical information, should precede drug prescribing. The interdisciplinary Pharmacogenetics Anticancer Agents Research (PAAR) group is an example of an excellent initiative to coordinate research on these issues. 196 Eventually, well-controlled prospective clinical trials with adequate sample size and statistical power will be needed to demonstrate the surplus value of such new concepts above current practice. 
DUALITY OF INTEREST
